Navigation Links
Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference
Date:11/3/2009

ROCKVILLE, Md., Nov. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held November 15-19, 2009 in Boston, Massachusetts. Presentations are listed below.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

  • Poster Session: Monday, November 16, 2009 - 12:30 p.m. - 2:30 p.m. Abstract No.: A106, "A Phase 1 study of ENMD-2076 in patients with relapsed or refractory acute myeloid leukemia (AML)," Halls C-D, 2nd floor.
  • Poster Session: Monday, November 16, 2009 - 12:30 p.m. - 2:30 p.m. Abstract No.: A156, "Mechanisms of resistance to Aurora kinase B inhibitors in leukemia: development and characterization of in vitro models," Halls C-D, 2nd floor.
  • Poster Session: Wednesday, November 18, 2009 - 12:30 p.m. - 2:30 p.m. Abstract No: C75, "A novel multi-targeted Aurora A and VEGFR2 kinase inhibitor, ENMD-2076, demonstrates synergistic antiproliferative and proapoptotic effects in combination with chemotherapy and trastuzumab in breast cancer cell lines," Halls C-D, 2nd floor.

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ENMD-2076 demonstrate significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to Aurora A kinase and other oncogenic proteins. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 targets a defined set of kinases, including Flt-3 and FGFR3, which have been shown to play important roles in the pathology of hematological cancers.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing primarily ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in Phase 1 studies in advanced cancers, multiple myeloma, and leukemia. The Company's other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway currently in multiple Phase 2 clinical trials for cancer, and ENMD-1198, a novel antimitotic agent currently in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem® in rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid®, risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

    CONTACT:
    Ginny Dunn
    Associate Director, Corporate Communications & Investor Relations
    EntreMed, Inc.
    240.864.2643

SOURCE EntreMed


'/>"/>
SOURCE EntreMed
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. EntreMed Focuses on Development of ENMD-2076
2. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
3. Nautica Malibu Triathlon Presented by Toyota Raises $718,000 for Childrens Hospital Los Angeles Pediatric Cancer Research
4. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
5. Success of Shape Up Somerville childhood obesity intervention to be presented
6. Survival data presented from phase II study of hormone-resistant prostate cancer patients
7. Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai
8. UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Presented at American Society for Dermatologic Surgery Annual Meeting
9. New Analyses of long-term LIALDA (mesalamine) data presented at ACG
10. Horizons AMI trial data to be presented at TCT 2007
11. AMIHOT II trial data presented at TCT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Worth, TX (PRWEB) , ... October 13, 2017 ... ... financial planning agency serving communities in the greater Dallas, Miami, and Raleigh regions, ... young boy fighting to overcome a rare and deadly chromosome abnormality. , After ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association of Eating ... excellence for the field of eating disorders, announces the opening of early registration ... Orlando, Florida at the Omni Resort at ChampionsGate. , The annual ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... , Oct. 4, 2017 ... single-use, self-contained, illuminating medical devices, today announced regulatory ... Health Surveillance Agency (or Agência Nacional de Vigilância ... first single-use, cordless surgical retractor with integrated LED ... optimal access, illumination and exposure of a tissue ...
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
Breaking Medicine Technology: